1. Home
  2. DNLI

DNLI

Denali Therapeutics Inc.

Logo Denali Therapeutics Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-17-2024 11:42am EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Founded: N/A Country:
United States
United States
Employees: 445 City: SOUTH SAN FRANCISCO
Market Cap: 2.4B IPO Year: 2017
Target Price: $47.20 AVG Volume (30 days): 1.2M
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.06 EPS Growth: N/A
52 Week Low/High: $15.45 - $33.31 Next Earning Date: 05-06-2024
Revenue: $330,531,000 Revenue Growth: 204.74%
Revenue Growth (this year): -71.95% Revenue Growth (next year): 106.60%

Share on Social Networks: